- Home
- GIGM vs LGVN Comparison
GIGM vs LGVN Comparison
Compare GIGM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- LGVN
- Stock Information
- Founded
- GIGM 1998
- LGVN 2014
- Country
- GIGM Taiwan
- LGVN United States
- Employees
- GIGM N/A
- LGVN N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- GIGM Technology
- LGVN Health Care
- Exchange
- GIGM Nasdaq
- LGVN Nasdaq
- Market Cap
- GIGM 17.8M
- LGVN 17.6M
- IPO Year
- GIGM 2000
- LGVN 2021
- Fundamental
- Price
- GIGM $1.58
- LGVN $0.71
- Analyst Decision
- GIGM
- LGVN Strong Buy
- Analyst Count
- GIGM 0
- LGVN 2
- Target Price
- GIGM N/A
- LGVN $6.50
- AVG Volume (30 Days)
- GIGM 6.8K
- LGVN 450.6K
- Earning Date
- GIGM 10-30-2025
- LGVN 11-04-2025
- Dividend Yield
- GIGM N/A
- LGVN N/A
- EPS Growth
- GIGM N/A
- LGVN N/A
- EPS
- GIGM N/A
- LGVN N/A
- Revenue
- GIGM $3,397,000.00
- LGVN $1,437,000.00
- Revenue This Year
- GIGM N/A
- LGVN N/A
- Revenue Next Year
- GIGM N/A
- LGVN N/A
- P/E Ratio
- GIGM N/A
- LGVN N/A
- Revenue Growth
- GIGM 10.11
- LGVN N/A
- 52 Week Low
- GIGM $1.38
- LGVN $0.62
- 52 Week High
- GIGM $1.89
- LGVN $2.31
- Technical
- Relative Strength Index (RSI)
- GIGM 39.01
- LGVN 33.96
- Support Level
- GIGM $1.58
- LGVN $0.62
- Resistance Level
- GIGM $1.66
- LGVN $0.79
- Average True Range (ATR)
- GIGM 0.04
- LGVN 0.05
- MACD
- GIGM -0.01
- LGVN -0.02
- Stochastic Oscillator
- GIGM 21.41
- LGVN 27.35
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.